Dimensional Fund Advisors LP Purchases 12,284 Shares of Agilent Technologies, Inc. $A

Key Points

• Dimensional Fund Advisors LP increased its stake in Agilent Technologies by 1.1%, acquiring an additional 12,284 shares, bringing its total holdings to approximately 1.16 million shares valued at $136 million.
• Agilent Technologies reported Q1 earnings per share of $1.31, surpassing analysts' estimates by $0.05, with revenues of $1.67 billion, up 6% year-over-year.
• Research analysts have varying ratings for Agilent Technologies, with a "Moderate Buy" consensus and price targets ranging from $125 to $150, reflecting differing outlooks on the company's performance.

Dimensional Fund Advisors LP boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,162,783 shares of the medical research company's stock after buying an additional 12,284 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.41% of Agilent Technologies worth $136,012,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after buying an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after buying an additional 2,371 shares in the last quarter. Alps Advisors Inc. lifted its holdings in Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after buying an additional 3,040 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after buying an additional 2,207 shares in the last quarter. Finally, LGT Capital Partners LTD. lifted its holdings in Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after buying an additional 54,302 shares in the last quarter.

Agilent Technologies Stock Up 0.4%

Shares of NYSE:A traded up $0.53 during trading hours on Wednesday, hitting $118.83. The company's stock had a trading volume of 1,690,137 shares, compared to its average volume of 1,274,930. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The company has a market capitalization of $33.76 billion, a price-to-earnings ratio of 29.34, a P/E/G ratio of 3.59 and a beta of 1.22. The firm's fifty day moving average price is $117.99 and its 200 day moving average price is $116.89.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business's revenue for the quarter was up 10.1% on a year-over-year basis. During the same period last year, the company posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Evercore ISI lifted their price objective on shares of Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. UBS Group decreased their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. Leerink Partners lifted their price objective on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a report on Friday, May 30th. Robert W. Baird reduced their price target on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a report on Thursday, May 22nd. Finally, Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus target price of $138.83.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.